TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immuron ( (IMRN) ) has shared an announcement.
On October 3, 2025, Immuron Limited announced an increase in the amount available for sale under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, raising the aggregate offering price to approximately $2,847,954. This strategic move is part of Immuron’s ongoing efforts to bolster its financial resources through the issuance and sale of American Depositary Shares (ADSs), which represent the company’s ordinary shares. The decision to expand the offering could potentially enhance Immuron’s market positioning by providing additional capital to support its operational and development activities.
The most recent analyst rating on (IMRN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Neutral.
Immuron’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis provides some positive momentum, but valuation remains a concern with a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited is an Australian company operating in the biotechnology industry. The company focuses on the development and commercialization of oral immunotherapeutic products for the treatment of immune-mediated and infectious diseases.
Average Trading Volume: 246,508
Technical Sentiment Signal: Hold
Current Market Cap: $15.05M
Learn more about IMRN stock on TipRanks’ Stock Analysis page.